Ogsiveo

News

Merck puts a price on its SpringWorks takeover bid

Merck KGaA has confirmed that talks to buy SpringWorks have advanced to the 'late-stage' and are revolving around an offer of around $47 per share.

News

Merck confirms its interest in buying SpringWorks

Merck KGaA has acknowledged that it is in talks to buy US cancer SpringWorks, but cautioned there is no guarantee a deal will be forthcoming.

News

FDA okays first therapy for desmoid tumours from SpringWorks

Pfizer spin-out SpringWorks Therapeutics has its first approved product after getting a green light from the FDA for Ogsiveo, the first-ever therapy for a rare type of non

Merck puts a price on its SpringWorks takeover bid

Merck confirms its interest in buying SpringWorks

FDA okays first therapy for desmoid tumours from SpringWorks

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks